Global Urinary Incontinence Therapeutics Market: Snapshot
Urinary incontinence therapeutics involve pelvic floor muscle strengthening and nerve stimulation products. Urinary continence therapeutics also involve combinational therapies with improved pharmacodynamics and pharmacokinetic properties. The urinary incontinence condition is detected using pelvic ultrasound or urodynamic testing. If diagnosed, the treatment for the condition involves a combination of medication and exercises.
At present, the therapeutics for urinary incontinence predominantly include a range of muscarinic receptor antagonists. The urinary incontinence therapeutics market has significant presence of generic drugs that limits the scope of innovation for improved safety and efficacy. The developmental pipeline for urinary incontinent is presently weak, with only 39 molecules that are in various phases of clinical development.
Urinary incontinence therapeutics involve surgical intervention as well. The most common one is sling procedure, in which the center part of the urethra is supported through surgery to minimize urine leakage.
Urinary incontinence is a common problem especially among individuals above the age of 50 and among individuals with some medical conditions. According to data by the American Academy of Family Physicians, more than 26 million Americans suffer from urinary incontinence at some point in their lives. The severity as well as the causative reasons vary from individual to individual. Weakened bladder, cancer, and damaged pelvic muscles are some of the causes of urinary incontinence. Urinary incontinence if not treated can have an adverse effect on the social, emotional, and economic life of an individual. Moreover, chronic urinary incontinence can have serious impact on the overall health of an individual.
Urinary incontinence, an involuntary leakage of urine, is a very common problem especially among people over 50 years of age. As per the American Academy of Family Physicians (AAFP), over 26 million Americans experience urinary incontinence at some point in their lives. This condition depends on the incontinence type and severity, along with its causative reason. Weakened bladder, damaged pelvic muscles, and cancer are some of the causes of urinary incontinence. This problem if not treated, affects the social, economic, and emotional life of persons affected by it, as chronic urinary incontinence can have a serious impact on overall health. The urinary incontinence condition is diagnosed using urodynamic testing or pelvic ultrasound. If diagnosed, the treatment for urinary incontinence involves a combination of various exercises along with medications.
The global urinary incontinence therapeutics market is expected to be driven by rising demand for treatment of urinary disorders, along with combinational therapies with improved pharmacokinetic and pharmacodynamic properties. Furthermore, rise in geriatric population, awareness initiatives along with invention of effective therapeutics from years of research and development by manufacturers, is expected to steer the growth of the global urinary incontinence therapeutics market. However, difficulty in disease diagnosis, along with negligence about urinary incontinence disorders is anticipated to restrain the market.
The global urinary incontinence therapeutics market has been classified on the basis of urinary incontinence type, therapeutic class, and distribution channels. Based on the type of urinary incontinence, the market has been categorized into stress urinary incontinence, urge urinary incontinence, functional urinary incontinence, overflow urinary incontinence, and mixed urinary incontinence. Among these segments, stress urinary incontinence affects more than 30 million Americans, and its prevalence is higher in women. Based on therapeutic class, the market has been divided into anticholinergic/antispasmodic agents, skeletal muscle relaxants, antidepressants, alpha blockers, and others. The others segment includes, but is not limited to beta-3 adrenergic agonists, topical estrogens, and serotonin – nor-epinephrine reuptake inhibitors. Recent advances in these therapeutic classes include the marketing of M3 specific anticholinergic drugs, which have low side effects due to increased bladder receptor sensitivity. Based on distribution channels, the global urinary incontinence therapeutics market has been segmented into hospital pharmacy stores, retail pharmacy stores, and online pharmacies.
The major challenge in the global urinary incontinence therapeutics market is the efficacy of these medications along with reducing their adverse effects. Recent new pharmacogenic advances in introduction of transdermal medications with better efficacy and tolerability than the conventional oral therapeutics serves as a major opportunity to the market. Counseling efforts from manufacturers with the help of various social organizations or NGOs is seen as a rising trend in the global urinary incontinence therapeutics market, which in turn is expected to increase therapeutic treatment adoption.
In terms of region, the global urinary incontinence therapeutics market has been divided into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is projected to experience exponential growth owing to increasing geriatric population, and increasing awareness about the treatment as well as diagnosis of overactive bladder conditions. North America is estimated to dominate the global urinary incontinence therapeutics market due to new and technologically advanced products introduced in the market and increasing specialty research initiatives in the field of urinary disorders. The global urinary incontinence therapeutics market is anticipated to experience high growth in pharma – emerging regions as several local manufacturers have a robust pipeline in the field of urinary incontinence research, due to the increasing demand for economic and efficient medications.
Key players in the global urinary incontinence therapeutics market are Johnson & Johnson (Janssen Global Services, LLC), Pfizer Inc., Astellas Pharma, Inc., ALLERGAN, Abbott, Sanofi, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Cytori Therapeutics Inc., and Atlantic Therapeutics among others.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.